EGFR and bladder transitional cell carcinoma: Oral genistein given 14–21 days before urothelial bladder cancer surgery was well-tolerated and reduced bladder cancer tissue phosphorylated-epidermal growth factor receptor (EGFR), which contributes to the proliferation and survival of cancer cells [407].